Peregrine Ventures today realized the USD 500 million exit from CartiHeal (USD 350 million down payment plus an additional USD 150 million milestone). This exit follows the portfolio company’s Food and Drug Administration (FDA) approval of the Agili-C™ implant for the treatment of cartilage and osteochondral defects. Having achieved this milestone, the medical device company’s…
eTurboNews članci su samo za pretplatnike. Pretplata je BESPLATNO.
Pretplatnici se prijavljuju ovdje Kliknite ovdje da se pretplatite BESPLATNO
Pretplatnici se prijavljuju ovdje Kliknite ovdje da se pretplatite BESPLATNO
ŠTO ISKLJUČITI IZ OVOG ČLANKA:
- This exit follows the portfolio company’s Food and Drug Administration (FDA) approval of the Agili-C™ implant for the treatment of cartilage and osteochondral defects.
- Having achieved this milestone, the medical device company’s….
- Pretplata je BESPLATNA.
